Speaker illustration

Doctor Frank Kramer

Institute for Target Discovery / Biomarker, Bayer Schering Pharma AG, Wuppertal (Germany)

Evaluation of high sensitivity C-reactive protein in vericiguat-treated patients with heart failure with reduced ejection fraction

Event: Heart Failure 2018 & World Congress on Acute Heart Failure

Topic: Pharmacotherapy

Session: Chronic Heart Failure – Treatment

Thumbnail

This platform is supported by

logo Novo Nordisk